MAXCYTE, INC.·4

Jun 22, 4:26 PM ET

DOUGLAS RICHARD 4

Research Summary

AI-generated summary

Updated

MaxCyte Director Douglas Richard Receives RSU Award

What Happened Douglas Richard, a member of MaxCyte, Inc.'s (MXCT) board of directors, was granted a total of 80,000 restricted stock units (RSUs) on June 17, 2026. The grant consists of 30,421 RSUs reported as a direct award and 49,579 RSUs reported as a derivative award. No cash was paid for these awards (acquisition price $0).

Key Details

  • Transaction date: June 17, 2026; Filing date (Form 4): June 22, 2026 (filed 5 days after the transaction).
  • Price: $0.00 per RSU (awarded, not purchased).
  • Shares: 30,421 direct RSUs + 49,579 derivative RSUs = 80,000 RSUs total.
  • Vesting: Shares underlying this annual director grant vest on June 17, 2027, subject to the reporting person's continuous service on the vesting date (per footnote).
  • Footnotes: F1 clarifies each RSU is a contingent right to one share of common stock; F2 states this is an annual grant under the company’s Equity Grant Policy for non-employee directors.
  • Shares owned after transaction: Not specified in the filing.
  • Timeliness: Filing appears late relative to the usual Form 4 requirement (filed 5 days after the June 17 transaction).

Context RSUs are awards representing the right to receive shares in the future if vesting conditions are met; they are not open‑market purchases or sales. This grant is a routine, compensation-related award for a non-employee director and does not by itself indicate buying or selling sentiment. The derivative-classed portion simply reflects reporting convention for contingent rights to receive shares.